Myriad Appoints R. Bryan Riggsbee as Chief Financial Officer

SALT LAKE CITY, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of R. Bryan Riggsbee as executive vice president, Chief Financial Officer, and Treasurer effective October 16, 2014. Jim Evans will continue in his role as Chief Financial Officer through the transition to Mr. Riggsbee.

"I am delighted that Bryan will be joining Myriad as our CFO," said Pete Meldrum, president and CEO of Myriad. "Myriad is a pioneer in the molecular diagnostic industry and Bryan's unique skill set is exceptionally well suited for Myriad as we look to execute on our business strategy."

"This is a great time to join Myriad, with its strong commitment to launching novel products that benefit patients," said Mr. Riggsbee. "I look forward to working with the Myriad team in advancing Myriad as a global molecular diagnostics leader."

Mr. Riggsbee most recently served as the senior vice president, Corporate Finance at Laboratory Corporation of America Holdings, a $5.8 billion clinical laboratory company, where he oversaw the financial planning and analysis (FP&A) and treasury functions. Previously, he served in various finance positions of increasing responsibility at General Electric Company. Mr Riggsbee began his career in the audit division of KPMG.

Mr. Riggsbee received a Masters of Business Administration degree from Northwestern University, Bachelor of Arts degree in Accounting from North Carolina State University and a Bachelor of Arts degree in Political Science from the University of North Carolina, Chapel Hill. Mr. Riggsbee is a Certified Public Accountant licensed in the state of North Carolina.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, HRD, Vectra DA and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the appointment and commencement of Mr. Riggsbee as an EVP, CFO, and Treasurer at the company; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Source:Myriad Genetics, Inc.